SCYNEXIS, Inc. (SCYX)
SCYNEXIS, Inc. operates in the Medical - Pharmaceuticals industry of the Healthcare sector, headquartered in Jersey City, NJ, US. The stock last traded at $4.85, up 0.31% on the session, giving a market capitalisation of $30.5M. On trailing twelve-month figures it carries a trailing P/E of -2.65, a net margin of -53.3%. Its beta of 1.10 implies it has historically moved more than the broad market.
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
SCYNEXIS, Inc. is most often compared with the following Healthcare names: